CTLA4 and melanoma: Ipilimumab was the first ICI authorized by the FDA in 2011; it serves as an antibody against CTLA-4 that can be used to treat advanced melanoma via suppression of the inhibitory signal of CTLA-4 to induce activated CTL [39].